(Q37490929)

20 August 2017

1 reference

title

Efalizumab discontinuation: a practical strategy (English)

1 reference

20 August 2017

Rupa Pugashetti

1

1 reference

20 August 2017

John Koo

series ordinal

2

1 reference

20 August 2017

publication date

1 January 2009

1 reference

Journal of Dermatological Treatment

20 August 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

20 August 2017

volume

20

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

132-136

1 reference

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09546630902984596

Relapse, rebound, and psoriasis adverse events: an advisory group report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630902984596

Efalizumab: a review of events reported during clinical trials and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630902984596

Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630902984596

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630902984596

10.1080/09546630902984596

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference